Annals

Advances Against Aspergillosis II

Edited by Edited by Karl V. Clemons (California Institute for Medical Research, San Jose, California), Malcolm Richardson (Wythenshawe Hospital, Manchester, UK), and David S. Perlin (New Jersey Medical School-UMDNJ, Newark, New Jersey)
Explore the Table of Contents
Advances Against Aspergillosis II

Published: December 2012

Volume 1273

Learn More

Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge—particularly in the face of increasing antifungal resistance. Bringing together the world’s leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the “Advances Against Aspergillosis” conference was held January 26–28, 2012 in Istanbul, Turkey. Among the topics included are the evolution of modular conidiophore development in the aspergilli; diverse applications of RNA-seq for functional genomics studies in Aspergillus fumigatus; protein targets for broad-spectrum mycosis vaccines: quantitative proteomic analysis of Aspergillus and Coccidioides; activation of the neutrophil NADPH oxidase by A. fumigatus; and cell biology of the innate immune response to A. fumigatus.